BMEZ:NYE-BlackRock Health Sciences Trust II (USD)

COMMON STOCK | |

Last Closing

USD 14.44

Change

-0.22 (-1.50)%

Market Cap

USD 1.64B

Volume

0.70M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-30 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TBB AT&T Inc

-0.01 (-0.04%)

USD 148.15B
PRS Prudential Financial Inc

+0.44 (+1.89%)

USD 44.13B
ALL-PB The Allstate Corporation

+0.25 (+0.99%)

USD 33.92B
SOJC Southern Co

+0.38 (+1.73%)

USD 22.61B
AIZN Assurant Inc

+0.37 (+1.84%)

USD 9.38B
RZB Reinsurance Group of America I..

+0.16 (+0.65%)

USD 8.62B
PCG-PA Pacific Gas and Electric Compa..

-0.23 (-0.94%)

USD 6.40B
PCG-PB Pacific Gas and Electric Compa..

-0.26 (-1.24%)

USD 5.68B
UNMA Unum Group

+0.57 (+2.41%)

USD 5.61B
PCG-PE Pacific Gas and Electric Compa..

N/A

USD 5.21B

ETFs Containing BMEZ

PCEF Invesco CEF Income Compos.. 0.00 % 0.50 %

+0.03 (+0.69%)

USD 0.81B
YYY Amplify High Income ETF 0.00 % 0.50 %

+0.08 (+0.69%)

USD 0.54B

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.43% N/A N/A 34% F
Dividend Return 10.32% N/A N/A 94% A
Total Return 8.89% N/A N/A 53% F
Trailing 12 Months  
Capital Gain -1.43% N/A N/A 34% F
Dividend Return 10.32% N/A N/A 94% A
Total Return 8.89% N/A N/A 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.74% N/A N/A 11% F
Dividend Return 0.54% N/A N/A 24% F
Total Return 6.29% N/A N/A 89% A-
Risk Return Profile  
Volatility (Standard Deviation) 24.82% N/A N/A 44% F
Risk Adjusted Return 2.18% N/A N/A 22% F
Market Capitalization 1.64B N/A N/A 65% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike